A Prospective, Randomized, Double-blind, Double dummy, Multi Centre, Comparative Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ivabradine Prolonged Release Tablets in Patients with Stable Chronic Heart Failure with Systolic Dysfunction
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Ivabradine (Primary) ; Ivabradine
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Healthcare
- 05 Nov 2019 Status changed from recruiting to completed.
- 22 Jun 2018 New trial record
- 18 Jun 2018 Status changed from not yet recruiting to recruiting.